Impedimed Ltd (IPD) - Total Liabilities
Based on the latest financial reports, Impedimed Ltd (IPD) has total liabilities worth AU$29.34 Million AUD (≈ $20.76 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Impedimed Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Impedimed Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Impedimed Ltd's total liabilities have evolved over time, based on quarterly financial data.
Impedimed Ltd Competitors by Total Liabilities
The table below lists competitors of Impedimed Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
India | Rs340.59 Million |
|
NuCana PLC
NASDAQ:NCNA
|
USA | $5.50 Million |
|
Pacific Assets Trust plc
LSE:PAC
|
UK | GBX6.88 Million |
|
Till Capital Ltd
V:TIL
|
Canada | CA$147.08K |
|
Hybrid Financial Services Limited
NSE:HYBRIDFIN
|
India | Rs108.44 Million |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
Malaysia | RM37.42 Million |
|
S-Energy Co.Ltd
KQ:095910
|
Korea | ₩161.54 Billion |
|
Rathdowney Resources Ltd
V:RTH
|
Canada | CA$17.57 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Impedimed Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Impedimed Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Impedimed Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Impedimed Ltd (2006–2025)
The table below shows the annual total liabilities of Impedimed Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$21.16 Million ≈ $14.97 Million |
+239.00% |
| 2024-06-30 | AU$6.24 Million ≈ $4.42 Million |
-20.54% |
| 2023-06-30 | AU$7.86 Million ≈ $5.56 Million |
+2.64% |
| 2022-06-30 | AU$7.66 Million ≈ $5.42 Million |
-11.92% |
| 2021-06-30 | AU$8.69 Million ≈ $6.15 Million |
+52.39% |
| 2020-06-30 | AU$5.70 Million ≈ $4.04 Million |
-16.08% |
| 2019-06-30 | AU$6.80 Million ≈ $4.81 Million |
+17.88% |
| 2018-06-30 | AU$5.76 Million ≈ $4.08 Million |
+3.95% |
| 2017-06-30 | AU$5.55 Million ≈ $3.92 Million |
+4.33% |
| 2016-06-30 | AU$5.32 Million ≈ $3.76 Million |
+72.60% |
| 2015-06-30 | AU$3.08 Million ≈ $2.18 Million |
+115.99% |
| 2014-06-30 | AU$1.43 Million ≈ $1.01 Million |
+12.28% |
| 2013-06-30 | AU$1.27 Million ≈ $898.61K |
-44.88% |
| 2012-06-30 | AU$2.30 Million ≈ $1.63 Million |
+8.58% |
| 2011-06-30 | AU$2.12 Million ≈ $1.50 Million |
-20.82% |
| 2010-06-30 | AU$2.68 Million ≈ $1.90 Million |
-11.58% |
| 2009-06-30 | AU$3.03 Million ≈ $2.14 Million |
+36.85% |
| 2008-06-30 | AU$2.21 Million ≈ $1.57 Million |
-7.16% |
| 2007-06-30 | AU$2.39 Million ≈ $1.69 Million |
-74.38% |
| 2006-06-30 | AU$9.31 Million ≈ $6.59 Million |
-- |
About Impedimed Ltd
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more